HSP Gp96 vaccine - Cure and Sure Biotech

Drug Profile

HSP Gp96 vaccine - Cure and Sure Biotech

Alternative Names: Autologous Gp96 vaccine - Cure & Sure Biotech; Autologous heat shock protein Gp96 vaccine - Cure & Sure Biotech; Autologous tumour derived HSP Gp96 vaccine - Cure & Sure Biotech; HSP Gp96 vaccine - Cure & Sure Biotech

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cure&Sure Biotech
  • Developer Chinese Academy of Medical Sciences; Chinese PLA General Hospital; Cure&Sure Biotech
  • Class Cancer vaccines; Protein-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Gastric cancer; Liver cancer; Pancreatic cancer
  • Phase I Glioblastoma

Most Recent Events

  • 24 Mar 2017 Phase-I/II development for Gastric cancer, Liver cancer, and Pancreatic cancer and Phase I development for Glioblastoma is ongoing in China (SC)
  • 01 Nov 2014 Phase-I/II clinical trials in Gastric cancer in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top